vs

Side-by-side financial comparison of LiveOne, Inc. (LVO) and SCYNEXIS INC (SCYX). Click either name above to swap in a different company.

LiveOne, Inc. is the larger business by last-quarter revenue ($20.3M vs $18.6M, roughly 1.1× SCYNEXIS INC). SCYNEXIS INC runs the higher net margin — 65.7% vs -20.1%, a 85.8% gap on every dollar of revenue. On growth, SCYNEXIS INC posted the faster year-over-year revenue change (1808.5% vs -31.2%). Over the past eight quarters, SCYNEXIS INC's revenue compounded faster (268.5% CAGR vs -19.0%).

Live Nation Entertainment, Inc. is an American multinational entertainment company that was founded in 2010 following the merger of Live Nation and Ticketmaster. It continues to operate both brands as subsidiary companies, promoting and managing ticket sales for live entertainment internationally. It also owns and operates entertainment venues and manages the careers of music artists.

SCYNEXIS Inc. is a biotechnology company focused on developing innovative antifungal therapies to address unmet medical needs for difficult-to-treat fungal infections. It targets hospital and specialty care markets, with key product candidates serving immunocompromised patients and other high-risk groups.

LVO vs SCYX — Head-to-Head

Bigger by revenue
LVO
LVO
1.1× larger
LVO
$20.3M
$18.6M
SCYX
Growing faster (revenue YoY)
SCYX
SCYX
+1839.7% gap
SCYX
1808.5%
-31.2%
LVO
Higher net margin
SCYX
SCYX
85.8% more per $
SCYX
65.7%
-20.1%
LVO
Faster 2-yr revenue CAGR
SCYX
SCYX
Annualised
SCYX
268.5%
-19.0%
LVO

Income Statement — Q3 FY2026 vs Q4 FY2025

Metric
LVO
LVO
SCYX
SCYX
Revenue
$20.3M
$18.6M
Net Profit
$-4.1M
$12.3M
Gross Margin
18.8%
Operating Margin
-9.6%
56.3%
Net Margin
-20.1%
65.7%
Revenue YoY
-31.2%
1808.5%
Net Profit YoY
22.3%
376.5%
EPS (diluted)
$0.25

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LVO
LVO
SCYX
SCYX
Q4 25
$20.3M
$18.6M
Q3 25
$18.8M
$334.0K
Q2 25
$19.2M
$1.4M
Q1 25
$19.3M
$257.0K
Q4 24
$29.4M
$977.0K
Q3 24
$32.6M
$660.0K
Q2 24
$33.1M
$736.0K
Q1 24
$30.9M
$1.4M
Net Profit
LVO
LVO
SCYX
SCYX
Q4 25
$-4.1M
$12.3M
Q3 25
$-5.5M
$-8.6M
Q2 25
$-3.6M
$-6.9M
Q1 25
$-10.4M
$-5.4M
Q4 24
$-5.2M
Q3 24
$-1.9M
$-2.8M
Q2 24
$-1.2M
$-14.5M
Q1 24
$-2.3M
$411.0K
Gross Margin
LVO
LVO
SCYX
SCYX
Q4 25
18.8%
Q3 25
13.8%
Q2 25
12.4%
Q1 25
30.8%
Q4 24
24.3%
Q3 24
24.8%
Q2 24
24.2%
Q1 24
25.5%
Operating Margin
LVO
LVO
SCYX
SCYX
Q4 25
-9.6%
56.3%
Q3 25
-24.4%
-2516.5%
Q2 25
-21.0%
-701.0%
Q1 25
-55.8%
-3350.2%
Q4 24
-17.4%
Q3 24
-4.3%
-1563.6%
Q2 24
-2.4%
-1255.0%
Q1 24
-3.7%
-692.5%
Net Margin
LVO
LVO
SCYX
SCYX
Q4 25
-20.1%
65.7%
Q3 25
-29.5%
-2572.2%
Q2 25
-18.7%
-504.8%
Q1 25
-54.2%
-2097.7%
Q4 24
-17.8%
Q3 24
-5.7%
-425.5%
Q2 24
-3.5%
-1964.4%
Q1 24
-7.4%
29.9%
EPS (diluted)
LVO
LVO
SCYX
SCYX
Q4 25
$0.25
Q3 25
$-0.17
Q2 25
$-0.14
Q1 25
$-0.11
Q4 24
Q3 24
$-0.06
Q2 24
$-0.30
Q1 24
$0.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LVO
LVO
SCYX
SCYX
Cash + ST InvestmentsLiquidity on hand
$8.6M
$40.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$-19.0M
$49.4M
Total Assets
$52.3M
$59.0M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LVO
LVO
SCYX
SCYX
Q4 25
$8.6M
$40.0M
Q3 25
$11.7M
$37.9M
Q2 25
$11.9M
$44.8M
Q1 25
$4.1M
$40.6M
Q4 24
$10.9M
$59.3M
Q3 24
$11.1M
$68.8M
Q2 24
$6.2M
$73.0M
Q1 24
$7.0M
$80.2M
Stockholders' Equity
LVO
LVO
SCYX
SCYX
Q4 25
$-19.0M
$49.4M
Q3 25
$-16.2M
$36.4M
Q2 25
$-20.8M
$44.5M
Q1 25
$-17.8M
$50.5M
Q4 24
$-8.4M
$55.1M
Q3 24
$-4.7M
$58.5M
Q2 24
$-3.8M
$60.4M
Q1 24
$-8.7M
$74.1M
Total Assets
LVO
LVO
SCYX
SCYX
Q4 25
$52.3M
$59.0M
Q3 25
$53.8M
$51.1M
Q2 25
$48.9M
$60.7M
Q1 25
$40.5M
$67.9M
Q4 24
$56.2M
$90.6M
Q3 24
$67.2M
$99.0M
Q2 24
$64.6M
$107.8M
Q1 24
$63.9M
$118.3M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LVO
LVO
SCYX
SCYX
Operating Cash FlowLast quarter
$-2.3M
$18.4M
Free Cash FlowOCF − Capex
$-2.9M
FCF MarginFCF / Revenue
-14.4%
Capex IntensityCapex / Revenue
3.2%
Cash ConversionOCF / Net Profit
1.50×
TTM Free Cash FlowTrailing 4 quarters
$-16.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LVO
LVO
SCYX
SCYX
Q4 25
$-2.3M
$18.4M
Q3 25
$-3.2M
$-8.7M
Q2 25
$-3.0M
$-7.5M
Q1 25
$-4.3M
$-7.5M
Q4 24
$3.5M
$-24.0M
Q3 24
$5.8M
$765.0K
Q2 24
$1.3M
$-10.9M
Q1 24
$3.0M
$-4.0M
Free Cash Flow
LVO
LVO
SCYX
SCYX
Q4 25
$-2.9M
Q3 25
$-4.0M
Q2 25
$-4.1M
Q1 25
$-5.2M
Q4 24
$2.7M
Q3 24
$5.2M
Q2 24
$606.0K
Q1 24
$2.1M
FCF Margin
LVO
LVO
SCYX
SCYX
Q4 25
-14.4%
Q3 25
-21.5%
Q2 25
-21.2%
Q1 25
-26.9%
Q4 24
9.2%
Q3 24
15.9%
Q2 24
1.8%
Q1 24
6.8%
Capex Intensity
LVO
LVO
SCYX
SCYX
Q4 25
3.2%
Q3 25
4.4%
Q2 25
5.3%
Q1 25
4.8%
Q4 24
2.7%
Q3 24
1.8%
Q2 24
2.2%
Q1 24
3.1%
Cash Conversion
LVO
LVO
SCYX
SCYX
Q4 25
1.50×
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
-9.75×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

LVO
LVO

Advertising$15.8M78%
Membership Services$2.9M14%
Merchandising Revenue$1.6M8%

SCYX
SCYX

Glaxosmithkline Intellectual Property$17.2M92%
Products$1.4M8%

Related Comparisons